Title: | HB Vaccination in the Prevention of Viral Reactivation in Allogeneic Hematopoietic Stem Cell Transplantation Recipients with Previous HBV Infection |
Other Titles: | HB vaccine to prevent viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection |
Authors: | Onozawa, Masahiro Browse this author |
Hashino, Satoshi Browse this author →KAKEN DB |
Darmanin, Stephanie Browse this author |
Okada, Kohei Browse this author |
Morita, Rena Browse this author |
Takahata, Mutsumi Browse this author |
Shigematsu, Akio Browse this author |
Kahata, Kaoru Browse this author |
Kondo, Takeshi Browse this author |
Tanaka, Junji Browse this author →KAKEN DB |
Imamura, Masahiro Browse this author |
Asaka, Masahiro Browse this author |
Keywords: | hepatitis B virus |
reverse seroconversion |
reactivation of hepatitis |
vaccination |
recombinant hepatitis B vaccine |
Issue Date: | Nov-2008 |
Publisher: | Elsevier Inc. |
Journal Title: | Biology of Blood and Marrow Transplantation |
Volume: | 14 |
Issue: | 11 |
Start Page: | 1226 |
End Page: | 1230 |
Publisher DOI: | 10.1016/j.bbmt.2008.08.007 |
PMID: | 18940676 |
Abstract: | HBV-reverse seroconversion (RS) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a frequent late-onset complication in recipients with previous HBV infection. We conducted post-transplant HB vaccine intervention in 38 allo-HSCT recipients with previous HBV infection. Firstly, we followed the recipients without any intervention (historical control) until 2003; hence we commenced HB vaccination. Out of the patients who underwent transplantation after 2003, 13 recipients were immunized by a standard 3-dose regimen after immunosuppressant cessation (vaccine group), while 12 recipients were observed without any intervention (non-vaccine group). Eight of the 13 historical control group recipients and 3 of the 12 non-vaccine group recipients, but none of the 13 vaccine group recipients, suffered HBV-RS. Cumulative risks of HBV-RS at 3 years post-HSCT in the historical control, non-vaccine and vaccine groups were 41%, 39% and 0% respectively (P = 0.022). We therefore conclude that intervention with HB vaccines is significantly effective in preventing post-HSCT HBV-RS. |
Type: | article (author version) |
URI: | http://hdl.handle.net/2115/38729 |
Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|